The prevalence of obesity and type 2 diabetes (T2D) is increasing worldwide, and these two metabolic disorders are closely linked. Lifestyle modification, including weight loss and exercise, are effective treatments for T2D, but, unfortunately, most patients are unsuccessful at maintaining durable weight reduction and recidivism is all too common. Therefore, safe and efficatious drugs are required for successful treatment of T2D in a large proportion of subjects.
Seven transmembrane receptors (7TMRs), often termed G protein-coupled receptors (GPCRs), are the most common targets of therapeutic drugs today. Targeting GPCRs in metabolic tissues - such as adipose, liver, muscle, pancreatic islet, immune, and central nervous tissues - has emerged as a key stragety for the development of anti-diabetic compounds.
In the Oh lab, we are interested in studying the role of GPCRs in obesity, inflammation and T2D.